A detailed history of Cubist Systematic Strategies, LLC transactions in Novavax Inc stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 88,600 shares of NVAX stock, worth $714,116. This represents 0.01% of its overall portfolio holdings.

Number of Shares
88,600
Holding current value
$714,116
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$6.67 - $9.52 $351,815 - $502,141
-52,746 Reduced 99.43%
301 $2,000
Q1 2023

May 15, 2023

SELL
$5.76 - $12.48 $2.52 Million - $5.46 Million
-437,703 Reduced 89.19%
53,047 $367,000
Q4 2022

Feb 14, 2023

BUY
$8.86 - $25.04 $4.17 Million - $11.8 Million
471,178 Added 2407.41%
490,750 $5.04 Million
Q3 2022

Nov 14, 2022

SELL
$18.2 - $76.12 $126,308 - $528,272
-6,940 Reduced 26.18%
19,572 $356,000
Q2 2022

Aug 15, 2022

SELL
$36.28 - $75.29 $986,308 - $2.05 Million
-27,186 Reduced 50.63%
26,512 $1.36 Million
Q1 2022

May 16, 2022

BUY
$69.73 - $142.9 $2.01 Million - $4.12 Million
28,836 Added 115.98%
53,698 $3.96 Million
Q4 2021

Feb 14, 2022

BUY
$134.56 - $217.97 $2.99 Million - $4.84 Million
22,208 Added 836.77%
24,862 $3.56 Million
Q3 2021

Nov 15, 2021

SELL
$177.8 - $270.58 $1.88 Million - $2.87 Million
-10,600 Reduced 79.98%
2,654 $550,000
Q2 2021

Aug 16, 2021

BUY
$121.0 - $257.67 $1.01 Million - $2.16 Million
8,379 Added 171.88%
13,254 $2.81 Million
Q1 2021

May 17, 2021

SELL
$112.98 - $319.93 $115,804 - $327,928
-1,025 Reduced 17.37%
4,875 $884,000
Q4 2020

Feb 16, 2021

SELL
$78.74 - $139.5 $227,794 - $403,573
-2,893 Reduced 32.9%
5,900 $658,000
Q3 2020

Nov 16, 2020

BUY
$79.44 - $178.51 $464,485 - $1.04 Million
5,847 Added 198.47%
8,793 $953,000
Q2 2020

Aug 14, 2020

BUY
$13.86 - $83.61 $40,831 - $246,315
2,946 New
2,946 $246,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $630M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.